Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia

Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia

Dhiren Singh1,2, Daniel W O’Connor11Department of Psychological Medicine, Monash University, Melbourne, Australia; 2Peninsula Mental Health Service, Melbourne, AustraliaAbstract: Antipsychotic medication is the mainstay of treatment in elderly patients with psychosis. In recent ye...

Full description

Bibliographic Details
Main Authors:	Dhiren Singh, Daniel W O’Connor
Format:	Article
Language:	English
Published:	Dove Medical Press 2009-08-01
Series:	Clinical Interventions in Aging
Subjects:	risperidone long-acting injection old age efficacy safety
Online Access:	https://www.dovepress.com/efficacy-and-safety-of-risperidone-long-acting-injection-in-elderly-pe-peer-reviewed-article-CIA

Similar Items

Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study
by: Hikaru Hori, et al.
Published: (2018-03-01)

Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety
by: Zhao M, et al.
Published: (2023-04-01)

Modeling the Choice Between Risperidone Long-Acting Injectable and Generic Risperidone from the Perspective of a Japanese Hospital
by: Yusuke Nakamura, et al.
Published: (2019-08-01)

Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM
by: Litman R, et al.
Published: (2023-01-01)

Once-Monthly Subcutaneously Administered Risperidone in the Treatment of Schizophrenia: Patient Considerations
by: Tchobaniouk LV, et al.
Published: (2020-02-01)

Achieving long-term goals through early personalized management of schizophrenia: expert opinion on the role of a new fast-onset long-acting injectable antipsychotic
by: Antonio Vita, et al.
Published: (2023-01-01)

The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study
by: Walling DP, et al.
Published: (2021-10-01)

The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study [Corrigendum]
by: Walling DP, et al.
Published: (2022-06-01)

Efficacy and Safety of Risperidone Microspheres for Injection (Ⅱ) in the Treatment of Patients with Acute Schizophrenia
by: LI Qian, ZHANG Yunshu, YAN Baoping, WANG Jian, MA Yanjuan, WANG Yuan, QIN Yingjie, NA Long, REN Zhiyong, SUN Junwei, DENG Huaili, MA Hongjun, QU Xuehui, ZHOU Nan, SI Tianmei
Published: (2023-11-01)

Poly(Lactic Acid) Block Copolymers with Poly(Hexylene Succinate) as Microparticles for Long-Acting Injectables of Risperidone Drug
by: Iouliana Chrysafi, et al.
Published: (2022-09-01)

Population Pharmacokinetic Analysis to Support and Facilitate Switching from Risperidone Formulations to Rykindo in Patients with Schizophrenia
by: Wenyan Wang, et al.
Published: (2024-01-01)

Safety and efficacy of risperidone in children aged less than 5 years - A naturalistic observational study
by: Mahesh Kamte, et al.
Published: (2017-07-01)

Formulation development and pharmacokinetic studies of long acting in situ depot injection of risperidone
by: Vineet Dubey, et al.
Published: (2022-02-01)

Efficacy and safety of brand-risperidone versus similar-risperidone in elderly patients with neuropsychiatric disorders: A retrospective study
by: Jefferson Cunha Folquitto, et al.

An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use
by: Amy M. VandenBerg, PharmD, BCPP
Published: (2022-11-01)

Risperidone Controlled Release Microspheres Based on Poly(Lactic Acid)-Poly(Propylene Adipate) Novel Polymer Blends Appropriate for Long Acting Injectable Formulations
by: Stavroula Nanaki, et al.
Published: (2018-08-01)

An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia
by: Pandina Gahan, et al.
Published: (2012-06-01)

Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
by: Einarson Thomas R, et al.
Published: (2012-07-01)

The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) study: real-world clinical practice in schizophrenia
by: Kruti Joshi, et al.
Published: (2018-01-01)

Efficacy of low-dose risperidone in combination with sertraline in first-episode drug-naïve patients with schizophrenia: a randomized controlled open-label study
by: Xiaoe Lang, et al.
Published: (2023-07-01)

Randomized Controlled Trial of Paliperidone Extended Release Versus Risperidone for the Treatment of Methamphetamine-Associated Psychosis in Chinese Patients
by: Gang Wang, et al.
Published: (2020-04-01)

Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia
by: Hye Ok Kim, et al.
Published: (2020-01-01)

Sodium Valproate as an Adjunctive to Risperidone in Treatment of Schizophrenia
by: V Omrani Fard, et al.
Published: (2007-01-01)

A case report of eosinophilia associated with risperidone withdrawl in a patient with schizophrenia
by: E. Giourou, et al.
Published: (2022-06-01)

The Effect of Risperidone on Cognitive Symptoms of Schizophrenia : A Comparison with Haloperidol
by: R. Daneshmand, M.D., et al.
Published: (2007-09-01)

Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly
by: Jerson Laks, et al.
Published: (2001-12-01)

Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians
by: Citrome L, et al.
Published: (2022-01-01)

Costs and efficacy ofolanzapine and risperidone in schizophrenia
by: Vittorio Mapelli
Published: (2007-06-01)

Post-injection syndrome and olanzapine long-acting injection in patients with schizophrenia: A case series
by: Saheli Dey, et al.
Published: (2022-12-01)

The combination of long-acting injectable antipsychotics, a new key in resistant schizophrenia
by: M.F. Tascón Guerra, et al.
Published: (2022-06-01)

The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia
by: Milz R, et al.
Published: (2023-03-01)

The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection
by: Trevor A. Stump, PharmD, BCPP, et al.
Published: (2021-01-01)

The maintenance of modified electroconvulsive therapy combined with risperidone is better than risperidone alone in preventing relapse of schizophrenia and improving cognitive function
by: Ying Yang, et al.

Evaluating the Effect of 8-Week Treatment With Risperidone On Fasting Blood Glucose of Patients with Schizophrenia
by: Firouzeh Raisi, et al.
Published: (2007-09-01)

Evaluating the Effect of 8-Week Treatment With Risperidone On Fasting Blood Glucose of Patients with Schizophrenia
by: Firouzeh Raisi, et al.
Published: (2007-08-01)

Effect of Ginkgo biloba, Risperidone and Biperiden regimen in chronic schizophrenia
by: Nikfarjam M (MD), et al.
Published: (2012-05-01)

Relapse in patients with schizophrenia: a comparison between risperidone and haloperidol
by: Eduardo Pondé de Sena, et al.
Published: (2003-10-01)

Prescribing practice of long-acting injectable antipsychotics
by: Jisha M Lucca, et al.
Published: (2020-01-01)

Effect of Transition to Long-acting Injectable Antipsychotic Treatment on Care Burden in Schizophrenia
by: Elif Özcan Tozoğlu, et al.
Published: (2021-12-01)

Deep vein thrombosis associated with long-term use of risperidone
by: Kuldeep Singh Yadav, et al.
Published: (2016-01-01)